Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Short Interest Down 73.1% in April.
RespireRx Pharmaceuticals Short Interest Data
Change Vs. Previous Month: 73.07%
Short Interest Ratio / Days to Cover: 0.0
Last Record Date: April 15, 2024
Outstanding Shares: 774,680,000 shares
Percentage of Shares Shorted: 0.00%
https://mayfieldrecorder.com/2024/04/25/respirerx-pharmaceuticals-inc-otcmktsrspi-short-interest-down-73-1-in-april.html
https://www.marketbeat.com/stocks/OTCMKTS/RSPI/short-interest/
Nice pricing too, we wait patiently for the upswing in price.
$RSPI
Maybe. Self-imposed quiet period possibly?
It is odd that they have ignored the 10-k and shareholders which is unlike their history. As discussed on the forum, there could be early indications as to how the tier 3 NIH preclincals are shaping up and if positive, it is only logical that BP would gobble up control of the drug candidate asap.
Negotiations happen before LOU, and other formal stuff. Wonder if the silence is more people, companies planning, doing DD on a formal agreement of some kind. $100k sounds more like a bridge loan ...so maybe they are near a really stupendous announcement for how they will be going forward?
LOL, well if that is their intent, they are doing a really bad job at it!
No updates on OSA or any drug programs, no timelines/milestones, can't even get a 10-K out. Yet, somehow BOD memeber loans them 100K with only some warrants to back it up. Silence still speaks.
When is the next pump? More needs to cash out. - Jeff
.05++ coming soon imo this is undiscovered imo
https://www.marketreportsworld.com/TOC/26519731?trk=article-ssr-frontend-pulse_little-text-block
GLOBAL EXPLODING HEAD SYNDROME TREATMENT INDUSTRY TRENDS ANALYSIS REPORT 2024, FORECAST TO 2032 (BROKEN DOWN BY TYPE, END USER, REGIONAL ANALYSIS, AND COMPETITIVE LANDSCAPE)
From the table of contents:
“8 Leading Companies Profiles
8.1 Respirerx Pharmaceuticals
8.1.1 Respirerx Pharmaceuticals Corporation Information
8.1.2 Respirerx Pharmaceuticals - Exploding Head Syndrome Treatment Product Portfolio and Specification
8.1.3 Respirerx Pharmaceuticals Performance Analysis (2019-2024)
8.1.4 Respirerx Pharmaceuticals Business and Markets Served
8.1.5 Respirerx Pharmaceuticals Recent Developments
8.2 Jazz Pharmaceutical
8.2.1 Jazz Pharmaceutical Corporation Information
8.2.2 Jazz Pharmaceutical - Exploding Head Syndrome Treatment Product Portfolio and Specification
8.2.3 Jazz Pharmaceutical Performance Analysis (2019-2024)
8.2.4 Jazz Pharmaceutical Business and Markets Served
8.2.5 Jazz Pharmaceutical Recent Developments
8.3 Arena Pharmaceuticals
8.3.1 Arena Pharmaceuticals Corporation Information
8.3.2 Arena Pharmaceuticals - Exploding Head“
RSPI in with the big boys sharky
Nice info thanks:
HOLY SMOKES DID YOU LOOK AT THE COMPANIES RESPIRE IS LISTED WITH!!!!!!!!!!!!!!!!!!!!!
• Arena Pharmaceuticals
• Boehringer Ingelheim
• Fabre-Kramer Pharmaceuticals
• Jazz Pharmaceutical
• Merck & Co
• Glaxo Smith Kline
• Respirerx Pharmaceuticals
• Neurocrine Biosciences
1) Arena Pharmaceuticals was bought by Pfizer
Pfizer Completes Acquisition of Arena Pharmaceuticals
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals
2)Boehringer Ingelheim
As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim,
https://en.wikipedia.org/wiki/Boehringer_Ingelheim
3)Fabre-Kramer Pharmaceuticals, Inc.
Fabre-Kramer Pharmaceuticals, Inc. (“FKP” or the “Company”), was formed to identify, develop and commercialize psychotropic drugs with significant market potential.
https://fabrekramer.com/about-us/
4) Jazz Pharmaceutical
Jazz Pharmaceutical (JAZZ ) CURRENTLY TRADING AT $107.99
https://finance.yahoo.com/quote/JAZZ/
5) Merck & Co
Merck & Co (MRK) CURRENTLY TRADING AT $126.90
https://finance.yahoo.com/quote/MRK/
6) Glaxo Smith Kline
Glaxo Smith Kline (GSK) CURRENTLY TRADING AT $40.91
https://finance.yahoo.com/quote/GSK/
7) Neurocrine Biosciences
Neurocrine Biosciences CURRENTLY TRADING AT $139.08
https://finance.yahoo.com/quote/NBIX/
Some news, alternative indication for Respirerx RSPI pipeline, cited as key player.
A condition related to obstructive sleep apnea - exploding head syndrome (really!).
https://www.bigouden.tv/2024/04/23/traitement-du-syndrome-de-la-tete-qui-explose-analyse-du-marche-paysage-concurrentiel-facteurs-de-croissance-revenus-fabre-kramer-pharmaceuticals-jazz-pharmaceutical-merck-co/
“Les principaux acteurs sont également clairement ciblés dans le rapport, avec des faits et des chiffres mentionnés.
• Arena Pharmaceuticals
• Boehringer Ingelheim
• Fabre-Kramer Pharmaceuticals
• Jazz Pharmaceutical
• Merck & Co
• Glaxo Smith Kline
• Respirerx Pharmaceuticals
• Neurocrine Biosciences”
https://www.statsndata.org/report/exploding-head-syndrome-treatment-market-30870
“EXPLODING HEAD SYNDROME TREATMENT MARKET RESEARCH REPORT FOR 2023: EXPLORING FUTURE OPPORTUNITIES, EMERGING TRENDS, COMPREHENSIVE ANALYSIS, AND FORECAST UNTIL 2029
Key Players
Arena Pharmaceuticals
Boehringer Ingelheim
Fabre-Kramer Pharmaceuticals
Jazz Pharmaceutical
Merck & Co
Glaxo Smith Kline
Respirerx Pharmaceuticals
Neurocrine Biosciences”
I agree.
Even if you assume it takes the entire OS of 2 billion shares to satisfy all warrants and notes outstanding.... essentially fully diluted.. Probably wont be near that much...
.02 would be a 40 million mrkt cap
.08 would be a 160 million mrkt cap
Considering they have an OSA program supposedly "valued" around 20 million, that assuming they are completeing some preclinical work on the new formulations in preps to launch human trials in late stages. And their promising SCI/ADHD candidate is waiting funding to continue human trials in later stages as well.
And then the pain/epilepsy candidate progressing through NIH preclinicals, which if successful as they appear confident in, would open up grant funding for human trials. Which would then be a high profile candidate that could help mitigate opioids. I've seen other preclinical pharma deals in the 10's to hundreds of million upfront, with potential milestone payments dwarfing that. Feels just like accumulating at pennies on the dollar here. But for balance, there is still plenty of risk in pharma industry, huge thresholds have to be met to advance any drug candidate. And maybe that is just simply where this is at currently. Insiders and institutional according to filings appear to be lining up with equity positions that can possibly pay off massively if their drug candidates successfully advance. Success not guaranteed but if it happens, I think we all can imagine how quickly the stock will gain traction and become one of those OTC story stocks... IMO
I’m ready! This should be at least.02-.08+ right now! This is crazy at .0008 lol
I would take either ,
A buyout at $2.50-$5.00/share for the entire pipeline would be a sweet deal for a BP company looking to expand their horizons
IMO, a succesful drug candidate passing phase 3 human clinicals that can replace the awful impact of opioids for pain management is worth billions easily. Getting to that point takes funding and resources of a BP, so RSPI would give up majority of equity in that asset. Since their filings indicate many insiders are looking for a payment event to trigger equity compensatio, then I would expect a partnership with cash and milestone type payments. Whether BP wants to deal with OTC shenanagins, is another story. Maybe a buyout would be more desireable, but value increases exponentially with each passing of human clincals, phase 1,2,3...Maybe RSPI uplists to a higher exchange to pursue their other drug programs in the works.
All speculation of course but I think minimum dimes and quarters are possible with a BP deal. Makes the risk v. reward extremely attractive here.
I would tend to agree. Considering that NIH desires more expiditious results and assuming animal trials to test addicitive liability are well underway or in progress, I would think there should be some early indication as to whether there is anything to stall going directly into phase 1 human trials. BP would almost be necessary at this point or highly encouraged to pursue.
If they continue to get good results for the other potential drugs. Then I would lean towards a buyout. If it remains just one drug. Then a partnership is more likely. Either way. the share price jumps and we benefit as well as the rest of the world. Just the pain med alone would be a enormous to say the least. No guess but $5 a share is not unrealistic. The share structure of the company is pretty good without billions upon billions of outstanding shares.
What is your take a , partnership or buyout. If a buyout what are you thinking 5-10B with knowing what they would make over time
I'm only guessing and speculating here but... I think that BP would be using inside information on how the 3rd stage tests are going and if it looks like they will come out of tat stage with more good news. Then BP would probably pounce on it. BP would probably assume that NIH is involved and the drug market is looking for an answer to the addiction issue that plagues the world. They would want in knowing that the process should move quickly.
Is BP waiting for the pain drug to make it through the 3rd preclinical and the 1st clinical with people b4 having the scientific data it needs...knowing nothing about the chemistry, am wondering at what point any BP would consider continued positive progress the "point at which to pounce"?
Yes. I think BP is watching this with great interest. This has moved along quickly and they wont fall a sleep at the wheel and miss what's next for this company without having a hand in it. I feel it will drop without warning and be one of those OTC companies that runs off the chart before most people can even get near it.
Anyone thinking we will get news by August or sooner
Ladies and gentlemen..
We have a winner..
This is truly a POS!!!!!
DOWN DOWN DOWN!!
RSPI WAHT A POS!!!!
Ladies and gentlemen..
We have a winner..
This is truly a POS!!!!!
DOWN DOWN DOWN!!
RSPI WAHT A POS!!!!
I think for the few folks following this forum, likely the truck has been backed up, accumulated and set aside to allow the drug development efforts for OSA and especially the high profile KRM-II-81 to percolate and mature.
Even those doing cursory DD on pharma industry can understand the implications and value if the NIH greenlights KRM-II-81 currently in tier 3 preclinicals. The potential to mitigate the opioid crisis is astounding, and worth my speculative monies. Considering how undervalued this stock is, one could wake up one day and it open 10x higher and upward from there. That is how ridiculous I perceive this, but that is my opinion and to each their own.
As I continue to say...
For all you bulls....
Why are you not lifting the offer or bidding this stock higher???
There are only 712200 shares on the ask..lift that offer!!
Put your money where your mouth is...
Otherwise, stop pretending to be soooo bullish....
At these prices, you should be buy hand over fist...
Back the truck up and load up!!!
Unbelievable!!!
As I continue to say...
For all you bulls....
Why are you not lifting the offer or bidding this stock higher???
There are only 712200 shares on the ask..lift that offer!!
Put your money where your mouth is...
Otherwise, stop pretending to be soooo bullish....
At these prices, you should be buy hand over fist...
Back the truck up and load up!!!
Unbelievable!!!
I think you may be off a decimal, but needless to say, there has been chunk buys over the past 4 months and lately hardly any dollar volume to speak of. IMO, just a holding pattern until more info is known via 10-k, or some status update on OSA program or the pain/epilepsy tier 3 trials with NIH. I think it is a good sign that BOD memeber loans 100k with only the .0015 warrants to back it up. One would think if there was nothing of significance/value on the horizon, this would be unlikely. Easy accumulate and hold here.
It is interesting looking at other preclinical/IND/phase 1 big pharma deals. Some are anywhere from 10's of million to hundreds of million up front cash with milestone payments possibly well into the hundreds of millions. As the CEO stated if they pass tier 3 preclinicals, they will be open for grant money, but more than likely I would think be striking a similar deal of significance for BP to take the ball and run with it. Such would allow them to focus energy and funds then to one of the other drug platforms they have in the works.
Probably be a fairly boring stock until then I suppose, although as someone mentioned, that seems to be the best case scenario for stocks of this nature. Do nothing, and then strike massive deal, trade for nickels and dimes and more... GLTA.
12:08 est.
6 , purchases of over 100k, less than a million, so in the thousands of dollars...
2 purchases of over a million shares so over ten-thousands of dollars.
Bullish!
Still looking for 10-K filing that is late. However, did see they had an 8-K filing where a BOD member provided a loan, with warrants at .0015. Another example of insiders lining up with equity positions here.
Staying long, she will move eventually. Looking forward to phase 3 news ahead.
$RSPI
Thanks thought it was quite witty...lol.Nice buying today.
We’re getting there sharky. Cmon PENNYLAND
Any thoughts on when we could see any phase 3 news
Nice to see RSPI close up today
For your sake, I hope you are right. Do you truly believe that these guys are not going to keep diluting and then do another RS.
You eating crow.
closer to what?
Follow the money? While ridicule is usually the best non violent weapon, and bashers use that a lot, Bashers proly want to keep sp low as long as possible so they can weekly or monthly buy more shares until it pops. Einstein did 99 problems on a board but purposely put the wrong answer ladt for which he was soundly taken to rtask by the attending students? His point was one negative out of 99 got more attention than 98 out of 99 correct answers?
The bashers way of expressing negativity strikes me as juvenile at best and most actual juveniles can behave that way a lot of other places and get more attention?
So...they do it in hopes their negativity will keep others from buying until it pops?
Followers
|
345
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
51294
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 fly_fisherman Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |